J&J COVID-19 Vaccinations to Resume in the US
The decision comes from the US CDC Advisory Committee on Immunization Practices following the evaluation of data showing a rare adverse event involving blood clots in combination with low platelet counts within approximately one to two weeks following vaccination.
Johnson & Johnson announced on April 23, 2021 that vaccinations with its single-shot COVID-19 vaccine will resume for all adults aged 18 years and older in the US following a decision from United States Centers for Disease Control (CDC) and FDA.
The decision comes from the US CDC Advisory Committee on Immunization Practices following the evaluation of data showing a rare adverse event involving blood clots in combination with low platelet counts (thrombosis with thrombocytopenia) within approximately one to two weeks following vaccination, Johnson & Johnson said in a company press release. The company has updated the vaccine’s emergency use authorization fact sheets for vaccination providers, recipients, and caregivers to include information about the diagnosis and treatment of thrombosis with thrombocytopenia.
“As the global pandemic continues to devastate communities around the world, we believe a single-shot, easily transportable COVID-19 vaccine with demonstrated protection against multiple variants can help protect the health and safety of people everywhere,” said Paul Stoffels, chief scientific officer of Johnson & Johnson. “We will collaborate with health authorities around the world to educate healthcare professionals and the public to ensure this very rare event can be identified early and treated effectively.”
Source: Johnson & Johnson
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
